GlassScriptPhysician profile
Mikhail Chilingaryan
NPI 1356581201
$10,234.79
in general payments reported to CMS, 2019-2025
42 companies · $2,205 in 2025
The $2,205 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $475 · 2020: $354 · 2021: $1,005 · 2022: $1,470 · 2023: $2,538 · 2024: $2,186 · 2025: $2,205.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,930.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,930.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,503.23 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $1,477.74 | 2021-2025 | Vraylar, Linzess, Qulipta |
| Amgen INC. | $848.45 | 2020-2025 | Repatha, Otezla, Evenity |
| Glaxosmithkline, LLC. | $795.18 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $793.23 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Ardelyx, INC. | $593.40 | 2024-2025 | Ibsrela |
| Novo Nordisk INC | $584.39 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $542.69 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $396.20 | 2019-2024 | Jardiance, Tradjenta |
| Novartis Pharmaceuticals Corporation | $359.31 | 2021-2024 | |
| Almatica Pharma LLC | $239.00 | 2021-2025 | Loreev Xr, Teriparatide |
| Microtransponder, INC. | $232.62 | 2022-2024 | |
| Otsuka America Pharmaceutical, INC. | $215.05 | 2023-2025 | Rexulti |
| Scilex Pharmaceuticals INC. | $145.52 | 2022-2025 | Ztlido |
| Astellas Pharma US INC | $128.71 | 2022 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mikhail Chilingaryan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.